Biocon Ltd 2024 IR
The report highlights Biocon's performance for FY24, showcasing a 35% growth in consolidated revenue to INR 156,212 million, driven by its biosimilars business. Key achievements include the successful integration of the acquired Viatris biosimilars business across 120+ countries and the approval of Liraglutide in the UK. On the ESG front, the company reduced its Scope 1 and 2 emissions by 28,808 tCO2e and achieved 80% renewable power utilization in India. Additionally, Biocon improved its S&P Global ESG score to 63 and continued its inclusion in the DJSI Emerging Markets Index.
Company: Biocon Ltd
Sector: Health Care
Country: India
Year: 2024
Type: IR
Pages: 376
Biocon Ltd
Integrated Annual Report
The report highlights Biocon's performance for FY24, showcasing a 35% growth in consolidated revenue to INR 156,212 million, driven by its biosimilars business. Key achievements include the successful integration of the acquired Viatris biosimilars business across 120+ countries and the approval of Liraglutide in the UK. On the ESG front, the company reduced its Scope 1 and 2 emissions by 28,808 tCO2e and achieved 80% renewable power utilization in India. Additionally, Biocon improved its S&P Global ESG score to 63 and continued its inclusion in the DJSI Emerging Markets Index.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Published
Jul 11, 2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees